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INTRODUCTION
 • Patients presenting with hemolytic anemia, thrombocytopenia, and organ dysfunction in 
the intensive care unit are clinical emergencies and can be difficult to diagnose
 • The most common disorders with the above clinical features are thrombotic 
thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS), which are both 
rare but have different etiologies1,2
 • No definitive test for complement-mediated atypical HUS (aHUS) exists, but TTP can be 
excluded with ADAMTS13 activity level >5―10%3
 • Effective management for each disorder is distinct and should be initiated rapidly to avoid 
irreversible organ damage or death.2,3 Eculizumab, a terminal complement inhibitor, is the 
only approved treatment for aHUS4,5 with 4 prospective clinical trials demonstrating its 
safety and efficacy6-9
OBJECTIVE
 • To evaluate the effects of initiating eculizumab treatment ≤7 days or >7 days after 
presentation of aHUS on renal outcomes, using pooled data from the 4 previously described 
prospective clinical trials6-9
METHODS
 • Data from 4 phase 2, open-label, single-arm, prospective clinical trials including both 
pediatric and adult patients with aHUS (NCT00844545, NCT00844844, NCT00838513, 
NCT00844428, NCT01193348, NCT01194973) were pooled
 – Only data from patients who had a documented date of onset of the current  
aHUS manifestation and a baseline estimated glomerular filtration rate (eGFR) of  
<90 mL/min/1.73 m2 were included
 • eGFR changes from baseline and normalization (≥90 mL/min/1.73 m2) over time 
were evaluated
 – Results were stratified according to whether patients received eculizumab treatment  
≤7 days or >7 days after the current aHUS manifestation
 – Two-group t-tests were used to evaluate differences between the subgroups for changes 
from baseline in eGFR
 • Baseline characteristics were compared between the 2 groups using the Wilcoxon rank-
sum test for continuous variables and the Fischer exact test for categorical variables
 • Multivariate regressions using repeated measures analysis were performed to identify 
predictors of change in eGFR from baseline to 1 year
RESULTS
Patients
 • Data were pooled from 97 patients out of a total of 100 patients enrolled across the 
4 studies
 – Three patients were excluded from the analysis because date of onset of aHUS 
manifestations was missing or baseline eGFR was >90 mL/min/1.73 m2
 • The time from the current aHUS manifestation to starting treatment with eculizumab was:
 – ≤7 days in 21 patients 
 – >7 days in 76 patients 
 • Demographic and baseline clinical characteristics of the included patients are shown in 
Table 1
Table 1. Demographics and Baseline Clinical Characteristics 
Time to Treatment
Characteristic
≤7 days  
n=21
>7 days
n=76
All 
N=97 P Value*
Median age, years (range) 30 (0–69) 29 (0–80) 29 (0–80) –
Age group in years, n (%) 0.029†
<18 10 (48) 15 (20) 25 (26)
≥18 11 (52) 61 (80) 72 (74)
Female gender, n (%) 11 (52) 49 (64) 60 (62) 0.323†
Complement mutation or autoantibody, n (%) 0.133†
Any mutation or autoantibody 9 (43) 48 (63) 57 (59)
CFH mutation 5 (24) 19 (25) 24 (25)
No complement mutation or 
autoantibody, n (%)
12 (57) 28 (37) 40 (41)
Median time from last aHUS manifestation to 
eculizumab treatment, months (range)
0.13
(0.03–0.20)
1.02
(0.23–47.40)
 0.75
(0.03–47.40)
–
Median number of TMA events, n (range)
1
(1–6)
1
(1–9)
1
(1–9)
0.421†
Receiving PE/PI at baseline, n (%) 11 (52) 60 (79) 71 (73) 0.001†
Median PE/PI duration during last 
aHUS manifestation prior to first 
dose, months (range)
0.10
(0.03–0.20)
0.67
(0.03–46.46)
0.49
(0.03–46.46)
<0.001‡
Dialysis at baseline, n (%) 12 (57) 31 (41) 43 (44) 0.219†
Median dialysis duration during last 
aHUS manifestation prior to first dose,  
months (range)
0.05
(0.03–0.20)
0.39
(0.03–34.85)
0.30
(0.03–34.85)
0.007†
History of kidney transplantation, n (%) 7 (33) 19 (25) 26 (27) 0.578†
Median baseline platelet count x 109/L (range)
81.5
(18.0–193.0)
133.5
(16.0–420.5)
127.5
(16.0–420.5)
0.002‡
Platelet count <150 x 109/L, n (%) 19 (90) 45 (59) 64 (66) 0.008†
Median hemoglobin, mg/dL (range)
n=18
84.0
(41.0–117.0)
n=71
92.0
(54.0–131.0)
n=89
89.0
(41.0–131.0)
0.122‡
Median LDH, U/L (range)
669.1
(131.0–7164.0)
297.5
(134.0–3682.0)
343.0
(131.0–7164.0)
<0.001‡
Median creatinine, µmol/L (range)
n=20
214.0
(112.0–1007.8)
n=74
243.1
(28.0–1169.6)
n=94
238.7
(28.0–1169.6)
0.708‡
Median baseline eGFR, mL/min/1.73 m2 
(range)§
11.0
(5.6–53.2)
16.0
(7.3–76.1)
15.9
(5.6–76.1)
0.299‡
*Comparison between ≤7-day and >7-day groups; †P values calculated using the Fisher exact test; ‡P values calculated using the Wilcoxon rank-sum test; 
§eGFR for patients on dialysis was imputed to 10 mL/min/1.73 m2.
aHUS, atypical hemolytic uremic syndrome; CFH, complement factor H; eGFR, estimated glomerular filtration rate; LDH, lactate dehydrogenase; PE/PI, plasma 
exchange/plasma infusion; TMA, thrombotic microangiopathy.
Changes in eGFR
 • Patients in whom eculizumab treatment was initiated ≤7 days after the current aHUS 
manifestation had a greater improvement in eGFR than those initiating treatment after  
>7 days from 1 month onward (P<0.05) (Figure 1)
 – The mean changes from baseline in eGFR for patients starting eculizumab ≤7 days and 
>7 days after the current manifestation were 57 and 23 mL/min/1.73 m2, respectively, 
after 1 year
 • For all measured time points after baseline, the percentage of patients with sustained 
response in eGFR was significantly higher with earlier administration of eculizumab 
(P<0.05) at all time points (Figure 2)
Figure 1. Change From Baseline in eGFR Over Time
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Predictors of eGFR Improvement
 • Repeated measures analysis of baseline characteristics identified several demographic and 
clinical features that independently contributed to eGFR improvements (Table 2)
Table 2. Repeated Measures Analysis of eGFR Change From Baseline to  
Post-Treatment Through 12 Months
Effect*
Time to Treatment (Continuous Variable)
Coefficient P value
aHUS duration (day) -0.03 0.0181
Age group (child vs adult) - 0.0061
Baseline LDH (U/L) 0.01 0.0078
Baseline hemoglobin (g/L) -0.97 0.0002
Trial visit - <0.0001
Baseline eGFR 0.21 0.1964
*Interaction terms that remain significant in the final model are visit (scheduled post-dose visits in months) by time to treatment, visit by age group, visit by 
baseline LDH, visit by baseline hemoglobin, and age group by baseline hemoglobin.
aHUS, atypical hemolytic uremic syndrome; eGFR, estimated glomerular filtration rate; LDH, lactate dehydrogenase.
CONCLUSIONS
 • This pooled analysis indicates that patients treated with eculizumab within 7 days of 
presentation of aHUS manifestation had greater improvement in eGFR over time than 
patients in whom treatment was delayed
 – A higher percentage of patients who received eculizumab within 7 days had normal 
eGFR after 1 month of treatment which was sustained through 12 months
 • In addition to early treatment initiation with eculizumab, younger patient age, higher 
lactate dehydrogenase level, and lower hemoglobin level at baseline were associated 
with eGFR improvement 
 • These results further support the importance of rapid diagnosis and treatment of aHUS 
for recovery of renal function
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Effect of Early Initiation of Eculizumab in Patients With aHUS on Renal Outcomes: A Pooled Analysis
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INTRODUCTION
 • Patients presenting with hemolytic anemia, thrombocytopenia, and organ dysfunction in 
the intensive care unit are clinical emergencies and can be difficult to diagnose
 • The most common disorders with the above clinical features are thrombotic 
thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS), which are both 
rare but have different etiologies1,2
 • No definitive test for complement-mediated atypical HUS (aHUS) exists, but TTP can be 
excluded with ADAMTS13 activity level >5―10%3
 • Effective management for each disorder is distinct and should be initiated rapidly to avoid 
irreversible organ damage or death.2,3 Eculizumab, a terminal complement inhibitor, is the 
only approved treatment for aHUS4,5 with 4 prospective clinical trials demonstrating its 
safety and efficacy6-9
OBJECTIVE
 • To evaluate the effects of initiating eculizumab treatment ≤7 days or >7 days after 
presentation of aHUS on renal outcomes, using pooled data from the 4 previously described 
prospective clinical trials6-9
METHODS
 • Data from 4 phase 2, open-label, single-arm, prospective clinical trials including both 
pediatric and adult patients with aHUS (NCT00844545, NCT00844844, NCT00838513, 
NCT00844428, NCT01193348, NCT01194973) were pooled
 – Only data from patients who had a documented date of onset of the current  
aHUS manifestation and a baseline estimated glomerular filtration rate (eGFR) of  
<90 mL/min/1.73 m2 were included
 • eGFR changes from baseline and normalization (≥90 mL/min/1.73 m2) over time 
were evaluated
 – Results were stratified according to whether patients received eculizumab treatment  
≤7 days or >7 days after the current aHUS manifestation
 – Two-group t-tests were used to evaluate differences between the subgroups for changes 
from baseline in eGFR
 • Baseline characteristics were compared between the 2 groups using the Wilcoxon rank-
sum test for continuous variables and the Fischer exact test for categorical variables
 • Multivariate regressions using repeated measures analysis were performed to identify 
predictors of change in eGFR from baseline to 1 year
RESULTS
Patients
 • Data were pooled from 97 patients out of a total of 100 patients enrolled across the 
4 studies
 – Three patients were excluded from the analysis because date of onset of aHUS 
manifestations was missing or baseline eGFR was >90 mL/min/1.73 m2
 • The time from the current aHUS manifestation to starting treatment with eculizumab was:
 – ≤7 days in 21 patients 
 – >7 days in 76 patients 
 • Demographic and baseline clinical characteristics of the included patients are shown in 
Table 1
Table 1. Demographics and Baseline Clinical Characteristics 
Time to Treatment
Characteristic
≤7 days  
n=21
>7 days
n=76
All 
N=97 P Value*
Median age, years (range) 30 (0–69) 29 (0–80) 29 (0–80) –
Age group in years, n (%) 0.029†
<18 10 (48) 15 (20) 25 (26)
≥18 11 (52) 61 (80) 72 (74)
Female gender, n (%) 11 (52) 49 (64) 60 (62) 0.323†
Complement mutation or autoantibody, n (%) 0.133†
Any mutation or autoantibody 9 (43) 48 (63) 57 (59)
CFH mutation 5 (24) 19 (25) 24 (25)
No complement mutation or 
autoantibody, n (%)
12 (57) 28 (37) 40 (41)
Median time from last aHUS manifestation to 
eculizumab treatment, months (range)
0.13
(0.03–0.20)
1.02
(0.23–47.40)
 0.75
(0.03–47.40)
–
Median number of TMA events, n (range)
1
(1–6)
1
(1–9)
1
(1–9)
0.421†
Receiving PE/PI at baseline, n (%) 11 (52) 60 (79) 71 (73) 0.001†
Median PE/PI duration during last 
aHUS manifestation prior to first 
dose, months (range)
0.10
(0.03–0.20)
0.67
(0.03–46.46)
0.49
(0.03–46.46)
<0.001‡
Dialysis at baseline, n (%) 12 (57) 31 (41) 43 (44) 0.219†
Median dialysis duration during last 
aHUS manifestation prior to first dose,  
months (range)
0.05
(0.03–0.20)
0.39
(0.03–34.85)
0.30
(0.03–34.85)
0.007†
History of kidney transplantation, n (%) 7 (33) 19 (25) 26 (27) 0.578†
Median baseline platelet count x 109/L (range)
81.5
(18.0–193.0)
133.5
(16.0–420.5)
127.5
(16.0–420.5)
0.002‡
Platelet count <150 x 109/L, n (%) 19 (90) 45 (59) 64 (66) 0.008†
Median hemoglobin, mg/dL (range)
n=18
84.0
(41.0–117.0)
n=71
92.0
(54.0–131.0)
n=89
89.0
(41.0–131.0)
0.122‡
Median LDH, U/L (range)
669.1
(131.0–7164.0)
297.5
(134.0–3682.0)
343.0
(131.0–7164.0)
<0.001‡
Median creatinine, µmol/L (range)
n=20
214.0
(112.0–1007.8)
n=74
243.1
(28.0–1169.6)
n=94
238.7
(28.0–1169.6)
0.708‡
Median baseline eGFR, mL/min/1.73 m2 
(range)§
11.0
(5.6–53.2)
16.0
(7.3–76.1)
15.9
(5.6–76.1)
0.299‡
*Comparison between ≤7-day and >7-day groups; †P values calculated using the Fisher exact test; ‡P values calculated using the Wilcoxon rank-sum test; 
§eGFR for patients on dialysis was imputed to 10 mL/min/1.73 m2.
aHUS, atypical hemolytic uremic syndrome; CFH, complement factor H; eGFR, estimated glomerular filtration rate; LDH, lactate dehydrogenase; PE/PI, plasma 
exchange/plasma infusion; TMA, thrombotic microangiopathy.
Changes in eGFR
 • Patients in whom eculizumab treatment was initiated ≤7 days after the current aHUS 
manifestation had a greater improvement in eGFR than those initiating treatment after  
>7 days from 1 month onward (P<0.05) (Figure 1)
 – The mean changes from baseline in eGFR for patients starting eculizumab ≤7 days and 
>7 days after the current manifestation were 57 and 23 mL/min/1.73 m2, respectively, 
after 1 year
 • For all measured time points after baseline, the percentage of patients with sustained 
response in eGFR was significantly higher with earlier administration of eculizumab 
(P<0.05) at all time points (Figure 2)
Figure 1. Change From Baseline in eGFR Over Time
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Predictors of eGFR Improvement
 • Repeated measures analysis of baseline characteristics identified several demographic and 
clinical features that independently contributed to eGFR improvements (Table 2)
Table 2. Repeated Measures Analysis of eGFR Change From Baseline to  
Post-Treatment Through 12 Months
Effect*
Time to Treatment (Continuous Variable)
Coefficient P value
aHUS duration (day) -0.03 0.0181
Age group (child vs adult) - 0.0061
Baseline LDH (U/L) 0.01 0.0078
Baseline hemoglobin (g/L) -0.97 0.0002
Trial visit - <0.0001
Baseline eGFR 0.21 0.1964
*Interaction terms that remain significant in the final model are visit (scheduled post-dose visits in months) by time to treatment, visit by age group, visit by 
baseline LDH, visit by baseline hemoglobin, and age group by baseline hemoglobin.
aHUS, atypical hemolytic uremic syndrome; eGFR, estimated glomerular filtration rate; LDH, lactate dehydrogenase.
CONCLUSIONS
 • This pooled analysis indicates that patients treated with eculizumab within 7 days of 
presentation of aHUS manifestation had greater improvement in eGFR over time than 
patients in whom treatment was delayed
 – A higher percentage of patients who received eculizumab within 7 days had normal 
eGFR after 1 month of treatment which was sustained through 12 months
 • In addition to early treatment initiation with eculizumab, younger patient age, higher 
lactate dehydrogenase level, and lower hemoglobin level at baseline were associated 
with eGFR improvement 
 • These results further support the importance of rapid diagnosis and treatment of aHUS 
for recovery of renal function
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INTRODUCTION
 • Patients presenting with hemolytic anemia, thrombocytopenia, and organ dysfunction in 
the intensive care unit are clinical emergencies and can be difficult to diagnose
 • The most common disorders with the above clinical features are thrombotic 
thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS), which are both 
rare but have different etiologies1,2
 • No definitive test for complement-mediated atypical HUS (aHUS) exists, but TTP can be 
excluded with ADAMTS13 activity level >5―10%3
 • Effective management for each disorder is distinct and should be initiated rapidly to avoid 
irreversible organ damage or death.2,3 Eculizumab, a terminal complement inhibitor, is the 
only approved treatment for aHUS4,5 with 4 prospective clinical trials demonstrating its 
safety and efficacy6-9
OBJECTIVE
 • To evaluate the effects of initiating eculizumab treatment ≤7 days or >7 days after 
presentation of aHUS on renal outcomes, using pooled data from the 4 previously described 
prospective clinical trials6-9
METHODS
 • Data from 4 phase 2, open-label, single-arm, prospective clinical trials including both 
pediatric and adult patients with aHUS (NCT00844545, NCT00844844, NCT00838513, 
NCT00844428, NCT01193348, NCT01194973) were pooled
 – Only data from patients who had a documented date of onset of the current  
aHUS manifestation and a baseline estimated glomerular filtration rate (eGFR) of  
<90 mL/min/1.73 m2 were included
 • eGFR changes from baseline and normalization (≥90 mL/min/1.73 m2) over time 
were evaluated
 – Results were stratified according to whether patients received eculizumab treatment  
≤7 days or >7 days after the current aHUS manifestation
 – Two-group t-tests were used to evaluate differences between the subgroups for changes 
from baseline in eGFR
 • Baseline characteristics were compared between the 2 groups using the Wilcoxon rank-
sum test for continuous variables and the Fischer exact test for categorical variables
 • Multivariate regressions using repeated measures analysis were performed to identify 
predictors of change in eGFR from baseline to 1 year
RESULTS
Patients
 • Data were pooled from 97 patients out of a total of 100 patients enrolled across the 
4 studies
 – Three patients were excluded from the analysis because date of onset of aHUS 
manifestations was missing or baseline eGFR was >90 mL/min/1.73 m2
 • The time from the current aHUS manifestation to starting treatment with eculizumab was:
 – ≤7 days in 21 patients 
 – >7 days in 76 patients 
 • Demographic and baseline clinical characteristics of the included patients are shown in 
Table 1
Table 1. Demographics and Baseline Clinical Characteristics 
Time to Treatment
Characteristic
≤7 days  
n=21
>7 days
n=76
All 
N=97 P Value*
Median age, years (range) 30 (0–69) 29 (0–80) 29 (0–80) –
Age group in years, n (%) 0.029†
<18 10 (48) 15 (20) 25 (26)
≥18 11 (52) 61 (80) 72 (74)
Female gender, n (%) 11 (52) 49 (64) 60 (62) 0.323†
Complement mutation or autoantibody, n (%) 0.133†
Any mutation or autoantibody 9 (43) 48 (63) 57 (59)
CFH mutation 5 (24) 19 (25) 24 (25)
No complement mutation or 
autoantibody, n (%)
12 (57) 28 (37) 40 (41)
Median time from last aHUS manifestation to 
eculizumab treatment, months (range)
0.13
(0.03–0.20)
1.02
(0.23–47.40)
 0.75
(0.03–47.40)
–
Median number of TMA events, n (range)
1
(1–6)
1
(1–9)
1
(1–9)
0.421†
Receiving PE/PI at baseline, n (%) 11 (52) 60 (79) 71 (73) 0.001†
Median PE/PI duration during last 
aHUS manifestation prior to first 
dose, months (range)
0.10
(0.03–0.20)
0.67
(0.03–46.46)
0.49
(0.03–46.46)
<0.001‡
Dialysis at baseline, n (%) 12 (57) 31 (41) 43 (44) 0.219†
Median dialysis duration during last 
aHUS manifestation prior to first dose,  
months (range)
0.05
(0.03–0.20)
0.39
(0.03–34.85)
0.30
(0.03–34.85)
0.007†
History of kidney transplantation, n (%) 7 (33) 19 (25) 26 (27) 0.578†
Median baseline platelet count x 109/L (range)
81.5
(18.0–193.0)
133.5
(16.0–420.5)
127.5
(16.0–420.5)
0.002‡
Platelet count <150 x 109/L, n (%) 19 (90) 45 (59) 64 (66) 0.008†
Median hemoglobin, mg/dL (range)
n=18
84.0
(41.0–117.0)
n=71
92.0
(54.0–131.0)
n=89
89.0
(41.0–131.0)
0.122‡
Median LDH, U/L (range)
669.1
(131.0–7164.0)
297.5
(134.0–3682.0)
343.0
(131.0–7164.0)
<0.001‡
Median creatinine, µmol/L (range)
n=20
214.0
(112.0–1007.8)
n=74
243.1
(28.0–1169.6)
n=94
238.7
(28.0–1169.6)
0.708‡
Median baseline eGFR, mL/min/1.73 m2 
(range)§
11.0
(5.6–53.2)
16.0
(7.3–76.1)
15.9
(5.6–76.1)
0.299‡
*Comparison between ≤7-day and >7-day groups; †P values calculated using the Fisher exact test; ‡P values calculated using the Wilcoxon rank-sum test; 
§eGFR for patients on dialysis was imputed to 10 mL/min/1.73 m2.
aHUS, atypical hemolytic uremic syndrome; CFH, complement factor H; eGFR, estimated glomerular filtration rate; LDH, lactate dehydrogenase; PE/PI, plasma 
exchange/plasma infusion; TMA, thrombotic microangiopathy.
Changes in eGFR
 • Patients in whom eculizumab treatment was initiated ≤7 days after the current aHUS 
manifestation had a greater improvement in eGFR than those initiating treatment after  
>7 days from 1 month onward (P<0.05) (Figure 1)
 – The mean changes from baseline in eGFR for patients starting eculizumab ≤7 days and 
>7 days after the current manifestation were 57 and 23 mL/min/1.73 m2, respectively, 
after 1 year
 • For all measured time points after baseline, the percentage of patients with sustained 
response in eGFR was significantly higher with earlier administration of eculizumab 
(P<0.05) at all time points (Figure 2)
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Predictors of eGFR Improvement
 • Repeated measures analysis of baseline characteristics identified several demographic and 
clinical features that independently contributed to eGFR improvements (Table 2)
Table 2. Repeated Measures Analysis of eGFR Change From Baseline to  
Post-Treatment Through 12 Months
Effect*
Time to Treatment (Continuous Variable)
Coefficient P value
aHUS duration (day) -0.03 0.0181
Age group (child vs adult) - 0.0061
Baseline LDH (U/L) 0.01 0.0078
Baseline hemoglobin (g/L) -0.97 0.0002
Trial visit - <0.0001
Baseline eGFR 0.21 0.1964
*Interaction terms that remain significant in the final model are visit (scheduled post-dose visits in months) by time to treatment, visit by age group, visit by 
baseline LDH, visit by baseline hemoglobin, and age group by baseline hemoglobin.
aHUS, atypical hemolytic uremic syndrome; eGFR, estimated glomerular filtration rate; LDH, lactate dehydrogenase.
CONCLUSIONS
 • This pooled analysis indicates that patients treated with eculizumab within 7 days of 
presentation of aHUS manifestation had greater improvement in eGFR over time than 
patients in whom treatment was delayed
 – A higher percentage of patients who received eculizumab within 7 days had normal 
eGFR after 1 month of treatment which was sustained through 12 months
 • In addition to early treatment initiation with eculizumab, younger patient age, higher 
lactate dehydrogenase level, and lower hemoglobin level at baseline were associated 
with eGFR improvement 
 • These results further support the importance of rapid diagnosis and treatment of aHUS 
for recovery of renal function
REFERENCES
1. Noris M , Remuzzi G. N Engl J Med. 2009;361(17):1676-87.
2. George JN, Nester CM. N Engl J Med. 2014;371(7):654-66.
3. Campistol JM, et al. Nefrologia. 2015;35(5):421-47.
4. European Medicines Agency. Soliris (eculizumab) [summary of product characteristics], Paris, France: 
Alexion Europe SAS; 2015.
5. US Food and Drug Administration. Soliris (eculizumab) [prescribing information], Cheshire, CT: Alexion 
Pharmaceuticals, Inc.; 2014.
6. Fakhouri F, et al. J Am Soc Nephrol. 2013;24:49A-50A.
7. Legendre CM, et al. N Engl J Med. 2013;368(23):2169-81.
8. Licht C, et al. Kidney Int. 2015;87(5):1061-73.
9. Greenbaum LA, et al. J Am Soc Nephrol. 2013;24:821A-2A.
ACKNOWLEDGMENTS
The authors would like to acknowledge Peloton Advantage, LLC, which provided editorial 
support with funding from Alexion Pharmaceuticals, Inc.
971
Presented at the Society of Critical Care Medicine (SCCM) 45th Critical Care Congress, February 20–24, 2016, Orlando, FL.
Effect of Early Initiation of Eculizumab in Patients With aHUS on Renal Outcomes: A Pooled Analysis
John F. Kincaid,1 Spero R. Cataland,2 Johan Vande Walle,3 Yahsou Delmas,4 Gianluigi Ardissino,5 Jimmy Wang1 
1Alexion Pharmaceuticals, Inc., Cheshire, CT, USA; 2Ohio State University, Columbus, OH, USA; 3University Hospital Ghent, Ghent, Belgium; 4Centre Hospitalier Universitaire, Bordeaux, France; 5Ospedale Maggiore Policlinico, Milan, Italy
INTRODUCTION
 • Patients presenting with hemolytic anemia, thrombocytopenia, and organ dysfunction in 
the intensive care unit are clinical emergencies and can be difficult to diagnose
 • The most common disorders with the above clinical features are thrombotic 
thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS), which are both 
rare but have different etiologies1,2
 • No definitive test for complement-mediated atypical HUS (aHUS) exists, but TTP can be 
excluded with ADAMTS13 activity level >5―10%3
 • Effective management for each disorder is distinct and should be initiated rapidly to avoid 
irreversible organ damage or death.2,3 Eculizumab, a terminal complement inhibitor, is the 
only approved treatment for aHUS4,5 with 4 prospective clinical trials demonstrating its 
safety and efficacy6-9
OBJECTIVE
 • To evaluate the effects of initiating eculizumab treatment ≤7 days or >7 days after 
presentation of aHUS on renal outcomes, using pooled data from the 4 previously described 
prospective clinical trials6-9
METHODS
 • Data from 4 phase 2, open-label, single-arm, prospective clinical trials including both 
pediatric and adult patients with aHUS (NCT00844545, NCT00844844, NCT00838513, 
NCT00844428, NCT01193348, NCT01194973) were pooled
 – Only data from patients who had a documented date of onset of the current  
aHUS manifestation and a baseline estimated glomerular filtration rate (eGFR) of  
<90 mL/min/1.73 m2 were included
 • eGFR changes from baseline and normalization (≥90 mL/min/1.73 m2) over time 
were evaluated
 – Results were stratified according to whether patients received eculizumab treatment  
≤7 days or >7 days after the current aHUS manifestation
 – Two-group t-tests were used to evaluate differences between the subgroups for changes 
from baseline in eGFR
 • Baseline characteristics were compared between the 2 groups using the Wilcoxon rank-
sum test for continuous variables and the Fischer exact test for categorical variables
 • Multivariate regressions using repeated measures analysis were performed to identify 
predictors of change in eGFR from baseline to 1 year
RESULTS
Patients
 • Data were pooled from 97 patients out of a total of 100 patients enrolled across the 
4 studies
 – Three patients were excluded from the analysis because date of onset of aHUS 
manifestations was missing or baseline eGFR was >90 mL/min/1.73 m2
 • The time from the current aHUS manifestation to starting treatment with eculizumab was:
 – ≤7 days in 21 patients 
 – >7 days in 76 patients 
 • Demographic and baseline clinical characteristics of the included patients are shown in 
Table 1
Table 1. Demographics and Baseline Clinical Characteristics 
Time to Treatment
Characteristic
≤7 days  
n=21
>7 days
n=76
All 
N=97 P Value*
Median age, years (range) 30 (0–69) 29 (0–80) 29 (0–80) –
Age group in years, n (%) 0.029†
<18 10 (48) 15 (20) 25 (26)
≥18 11 (52) 61 (80) 72 (74)
Female gender, n (%) 11 (52) 49 (64) 60 (62) 0.323†
Complement mutation or autoantibody, n (%) 0.133†
Any mutation or autoantibody 9 (43) 48 (63) 57 (59)
CFH mutation 5 (24) 19 (25) 24 (25)
No complement mutation or 
autoantibody, n (%)
12 (57) 28 (37) 40 (41)
Median time from last aHUS manifestation to 
eculizumab treatment, months (range)
0.13
(0.03–0.20)
1.02
(0.23–47.40)
 0.75
(0.03–47.40)
–
Median number of TMA events, n (range)
1
(1–6)
1
(1–9)
1
(1–9)
0.421†
Receiving PE/PI at baseline, n (%) 11 (52) 60 (79) 71 (73) 0.001†
Median PE/PI duration during last 
aHUS manifestation prior to first 
dose, months (range)
0.10
(0.03–0.20)
0.67
(0.03–46.46)
0.49
(0.03–46.46)
<0.001‡
Dialysis at baseline, n (%) 12 (57) 31 (41) 43 (44) 0.219†
Median dialysis duration during last 
aHUS manifestation prior to first dose,  
months (range)
0.05
(0.03–0.20)
0.39
(0.03–34.85)
0.30
(0.03–34.85)
0.007†
History of kidney transplantation, n (%) 7 (33) 19 (25) 26 (27) 0.578†
Median baseline platelet count x 109/L (range)
81.5
(18.0–193.0)
133.5
(16.0–420.5)
127.5
(16.0–420.5)
0.002‡
Platelet count <150 x 109/L, n (%) 19 (90) 45 (59) 64 (66) 0.008†
Median hemoglobin, mg/dL (range)
n=18
84.0
(41.0–117.0)
n=71
92.0
(54.0–131.0)
n=89
89.0
(41.0–131.0)
0.122‡
Median LDH, U/L (range)
669.1
(131.0–7164.0)
297.5
(134.0–3682.0)
343.0
(131.0–7164.0)
<0.001‡
Median creatinine, µmol/L (range)
n=20
214.0
(112.0–1007.8)
n=74
243.1
(28.0–1169.6)
n=94
238.7
(28.0–1169.6)
0.708‡
Median baseline eGFR, mL/min/1.73 m2 
(range)§
11.0
(5.6–53.2)
16.0
(7.3–76.1)
15.9
(5.6–76.1)
0.299‡
*Comparison between ≤7-day and >7-day groups; †P values calculated using the Fisher exact test; ‡P values calculated using the Wilcoxon rank-sum test; 
§eGFR for patients on dialysis was imputed to 10 mL/min/1.73 m2.
aHUS, atypical hemolytic uremic syndrome; CFH, complement factor H; eGFR, estimated glomerular filtration rate; LDH, lactate dehydrogenase; PE/PI, plasma 
exchange/plasma infusion; TMA, thrombotic microangiopathy.
Changes in eGFR
 • Patients in whom eculizumab treatment was initiated ≤7 days after the current aHUS 
manifestation had a greater improvement in eGFR than those initiating treatment after  
>7 days from 1 month onward (P<0.05) (Figure 1)
 – The mean changes from baseline in eGFR for patients starting eculizumab ≤7 days and 
>7 days after the current manifestation were 57 and 23 mL/min/1.73 m2, respectively, 
after 1 year
 • For all measured time points after baseline, the percentage of patients with sustained 
response in eGFR was significantly higher with earlier administration of eculizumab 
(P<0.05) at all time points (Figure 2)
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Predictors of eGFR Improvement
 • Repeated measures analysis of baseline characteristics identified several demographic and 
clinical features that independently contributed to eGFR improvements (Table 2)
Table 2. Repeated Measures Analysis of eGFR Change From Baseline to  
Post-Treatment Through 12 Months
Effect*
Time to Treatment (Continuous Variable)
Coefficient P value
aHUS duration (day) -0.03 0.0181
Age group (child vs adult) - 0.0061
Baseline LDH (U/L) 0.01 0.0078
Baseline hemoglobin (g/L) -0.97 0.0002
Trial visit - <0.0001
Baseline eGFR 0.21 0.1964
*Interaction terms that remain significant in the final model are visit (scheduled post-dose visits in months) by time to treatment, visit by age group, visit by 
baseline LDH, visit by baseline hemoglobin, and age group by baseline hemoglobin.
aHUS, atypical hemolytic uremic syndrome; eGFR, estimated glomerular filtration rate; LDH, lactate dehydrogenase.
CONCLUSIONS
 • This pooled analysis indicates that patients treated with eculizumab within 7 days of 
presentation of aHUS manifestation had greater improvement in eGFR over time than 
patients in whom treatment was delayed
 – A higher percentage of patients who received eculizumab within 7 days had normal 
eGFR after 1 month of treatment which was sustained through 12 months
 • In addition to early treatment initiation with eculizumab, younger patient age, higher 
lactate dehydrogenase level, and lower hemoglobin level at baseline were associated 
with eGFR improvement 
 • These results further support the importance of rapid diagnosis and treatment of aHUS 
for recovery of renal function
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INTRODUCTION
 • Patients presenting with hemolytic anemia, thrombocytopenia, and organ dysfunction in 
the intensive care unit are clinical emergencies and can be difficult to diagnose
 • The most common disorders with the above clinical features are thrombotic 
thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS), which are both 
rare but have different etiologies1,2
 • No definitive test for complement-mediated atypical HUS (aHUS) exists, but TTP can be 
excluded with ADAMTS13 activity level >5―10%3
 • Effective management for each disorder is distinct and should be initiated rapidly to avoid 
irreversible organ damage or death.2,3 Eculizumab, a terminal complement inhibitor, is the 
only approved treatment for aHUS4,5 with 4 prospective clinical trials demonstrating its 
safety and efficacy6-9
OBJECTIVE
 • To evaluate the effects of initiating eculizumab treatment ≤7 days or >7 days after 
presentation of aHUS on renal outcomes, using pooled data from the 4 previously described 
prospective clinical trials6-9
METHODS
 • Data from 4 phase 2, open-label, single-arm, prospective clinical trials including both 
pediatric and adult patients with aHUS (NCT00844545, NCT00844844, NCT00838513, 
NCT00844428, NCT01193348, NCT01194973) were pooled
 – Only data from patients who had a documented date of onset of the current  
aHUS manifestation and a baseline estimated glomerular filtration rate (eGFR) of  
<90 mL/min/1.73 m2 were included
 • eGFR changes from baseline and normalization (≥90 mL/min/1.73 m2) over time 
were evaluated
 – Results were stratified according to whether patients received eculizumab treatment  
≤7 days or >7 days after the current aHUS manifestation
 – Two-group t-tests were used to evaluate differences between the subgroups for changes 
from baseline in eGFR
 • Baseline characteristics were compared between the 2 groups using the Wilcoxon rank-
sum test for continuous variables and the Fischer exact test for categorical variables
 • Multivariate regressions using repeated measures analysis were performed to identify 
predictors of change in eGFR from baseline to 1 year
RESULTS
Patients
 • Data were pooled from 97 patients out of a total of 100 patients enrolled across the 
4 studies
 – Three patients were excluded from the analysis because date of onset of aHUS 
manifestations was missing or baseline eGFR was >90 mL/min/1.73 m2
 • The time from the current aHUS manifestation to starting treatment with eculizumab was:
 – ≤7 days in 21 patients 
 – >7 days in 76 patients 
 • Demographic and baseline clinical characteristics of the included patients are shown in 
Table 1
Table 1. Demographics and Baseline Clinical Characteristics 
Time to Treatment
Characteristic
≤7 days  
n=21
>7 days
n=76
All 
N=97 P Value*
Median age, years (range) 30 (0–69) 29 (0–80) 29 (0–80) –
Age group in years, n (%) 0.029†
<18 10 (48) 15 (20) 25 (26)
≥18 11 (52) 61 (80) 72 (74)
Female gender, n (%) 11 (52) 49 (64) 60 (62) 0.323†
Complement mutation or autoantibody, n (%) 0.133†
Any mutation or autoantibody 9 (43) 48 (63) 57 (59)
CFH mutation 5 (24) 19 (25) 24 (25)
No complement mutation or 
autoantibody, n (%)
12 (57) 28 (37) 40 (41)
Median time from last aHUS manifestation to 
eculizumab treatment, months (range)
0.13
(0.03–0.20)
1.02
(0.23–47.40)
 0.75
(0.03–47.40)
–
Median number of TMA events, n (range)
1
(1–6)
1
(1–9)
1
(1–9)
0.421†
Receiving PE/PI at baseline, n (%) 11 (52) 60 (79) 71 (73) 0.001†
Median PE/PI duration during last 
aHUS manifestation prior to first 
dose, months (range)
0.10
(0.03–0.20)
0.67
(0.03–46.46)
0.49
(0.03–46.46)
<0.001‡
Dialysis at baseline, n (%) 12 (57) 31 (41) 43 (44) 0.219†
Median dialysis duration during last 
aHUS manifestation prior to first dose,  
months (range)
0.05
(0.03–0.20)
0.39
(0.03–34.85)
0.30
(0.03–34.85)
0.007†
History of kidney transplantation, n (%) 7 (33) 19 (25) 26 (27) 0.578†
Median baseline platelet count x 109/L (range)
81.5
(18.0–193.0)
133.5
(16.0–420.5)
127.5
(16.0–420.5)
0.002‡
Platelet count <150 x 109/L, n (%) 19 (90) 45 (59) 64 (66) 0.008†
Median hemoglobin, mg/dL (range)
n=18
84.0
(41.0–117.0)
n=71
92.0
(54.0–131.0)
n=89
89.0
(41.0–131.0)
0.122‡
Median LDH, U/L (range)
669.1
(131.0–7164.0)
297.5
(134.0–3682.0)
343.0
(131.0–7164.0)
<0.001‡
Median creatinine, µmol/L (range)
n=20
214.0
(112.0–1007.8)
n=74
243.1
(28.0–1169.6)
n=94
238.7
(28.0–1169.6)
0.708‡
Median baseline eGFR, mL/min/1.73 m2 
(range)§
11.0
(5.6–53.2)
16.0
(7.3–76.1)
15.9
(5.6–76.1)
0.299‡
*Comparison between ≤7-day and >7-day groups; †P values calculated using the Fisher exact test; ‡P values calculated using the Wilcoxon rank-sum test; 
§eGFR for patients on dialysis was imputed to 10 mL/min/1.73 m2.
aHUS, atypical hemolytic uremic syndrome; CFH, complement factor H; eGFR, estimated glomerular filtration rate; LDH, lactate dehydrogenase; PE/PI, plasma 
exchange/plasma infusion; TMA, thrombotic microangiopathy.
Changes in eGFR
 • Patients in whom eculizumab treatment was initiated ≤7 days after the current aHUS 
manifestation had a greater improvement in eGFR than those initiating treatment after  
>7 days from 1 month onward (P<0.05) (Figure 1)
 – The mean changes from baseline in eGFR for patients starting eculizumab ≤7 days and 
>7 days after the current manifestation were 57 and 23 mL/min/1.73 m2, respectively, 
after 1 year
 • For all measured time points after baseline, the percentage of patients with sustained 
response in eGFR was significantly higher with earlier administration of eculizumab 
(P<0.05) at all time points (Figure 2)
Figure 1. Change From Baseline in eGFR Over Time
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Figure 2. Proportions of Patients With Sustained Response* in eGFR    
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Predictors of eGFR Improvement
 • Repeated measures analysis of baseline characteristics identified several demographic and 
clinical features that independently contributed to eGFR improvements (Table 2)
Table 2. Repeated Measures Analysis of eGFR Change From Baseline to  
Post-Treatment Through 12 Months
Effect*
Time to Treatment (Continuous Variable)
Coefficient P value
aHUS duration (day) -0.03 0.0181
Age group (child vs adult) - 0.0061
Baseline LDH (U/L) 0.01 0.0078
Baseline hemoglobin (g/L) -0.97 0.0002
Trial visit - <0.0001
Baseline eGFR 0.21 0.1964
*Interaction terms that remain significant in the final model are visit (scheduled post-dose visits in months) by time to treatment, visit by age group, visit by 
baseline LDH, visit by baseline hemoglobin, and age group by baseline hemoglobin.
aHUS, atypical hemolytic uremic syndrome; eGFR, estimated glomerular filtration rate; LDH, lactate dehydrogenase.
CONCLUSIONS
 • This pooled analysis indicates that patients treated with eculizumab within 7 days of 
presentation of aHUS manifestation had greater improvement in eGFR over time than 
patients in whom treatment was delayed
 – A higher percentage of patients who received eculizumab within 7 days had normal 
eGFR after 1 month of treatment which was sustained through 12 months
 • In addition to early treatment initiation with eculizumab, younger patient age, higher 
lactate dehydrogenase level, and lower hemoglobin level at baseline were associated 
with eGFR improvement 
 • These results further support the importance of rapid diagnosis and treatment of aHUS 
for recovery of renal function
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